Back to Cell Types

EoL-1Homo sapiens (Human)Cancer cell line

Also known as: AML-EOL-1, EoL-1 cell, EoL-1-cell, EOL1, EOL-1

🤖 AI SummaryBased on 6 publications

Quick Overview

EoL-1 is a human eosinophilic leukemia cell line used for studying MLL gene alterations and FIP1L1-PDGFRA fusion.

Detailed Summary

EoL-1 is a human eosinophilic leukemia cell line derived from a patient with chronic eosinophilic leukemia (CEL). It is characterized by the presence of the FIP1L1-PDGFRA fusion gene, which is a key driver in the pathogenesis of certain types of eosinophilic leukemia. This cell line is widely used in research to study the molecular mechanisms of MLL gene alterations and the role of tyrosine kinase inhibitors in treating leukemias with these genetic abnormalities. EoL-1 cells can be differentiated into eosinophils under specific culture conditions and are valuable for investigating the effects of targeted therapies on leukemic cells. The cell line has been utilized in studies to understand the genetic and molecular basis of eosinophilic disorders and to develop new therapeutic strategies.

Research Applications

Study of MLL gene alterationsInvestigation of FIP1L1-PDGFRA fusion geneDevelopment of targeted therapies for eosinophilic leukemiaAnalysis of tyrosine kinase inhibitor efficacy

Key Characteristics

Presence of FIP1L1-PDGFRA fusion geneAbility to differentiate into eosinophilsUse in studying MLL gene translocationsResponse to tyrosine kinase inhibitors

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0258
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	33
Age Category	Adult
Sex	Male

Disease Information

Disease	Chronic eosinophilic leukemia
Lineage	Myeloid
Subtype	Chronic Eosinophilic Leukemia, NOS
OncoTree Code	CELNOS

DepMap Information

Source Type	DSMZ
Source ID	ACH-000198_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
Gene fusion	FIP1L1	FIP1L1-PDGFRA	-	-	PubMed=23637631

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

7,10

D13S317

12,13

D16S539

8,10

D18S51

12,14

D19S433

12,13

D21S11

29

D2S1338

17,18

D3S1358

16,17

D5S818

11

D7S820

10,13

D8S1179

13

FGA

24

Penta D

7,10,11

Penta E

5,7

TH01

9.3

TPOX

8

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.

Drexler H.G., Quentmeier H., MacLeod R.A.F.

Leukemia 18:227-232(2004).

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Drexler H.G., Gilliland D.G.

Blood 103:2802-2805(2004).

Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.

Imaizumi M., Endo M., Takano N., Konno T.

Leukemia 10:102-105(1996).

Establishment and characterization of a new human eosinophilic leukemia cell line.

Yamada K., Machover D., Breard J., Mathe G.

Blood 66:1233-1240(1985).

EoL-1, a human eosinophilic cell line.";

Mayumi M.

Leuk. Lymphoma 7:243-250(1992).

Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.

Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.

Tissue Cult. Res. Commun. 15:211-219(1996).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).